New mRNA Vaccine Shows Promise in Treating Skin Cancer
New mRNA Vaccine Shows Promise in Treating Skin Cancer
Updated at: August 26, 2026 at 12:45 AM
A groundbreaking medical study has brought new hope to patients fighting melanoma.
A collaborative project between Moderna and Merck has successfully tested a personalized mRNA-based cancer vaccine, known as mRNA-4157, designed to prevent the recurrence of skin cancer.
In a large Phase 3 clinical trial, researchers found that combining this vaccine with the immunotherapy drug Keytruda significantly lowered the chances of the cancer returning or spreading compared to using the drug alone.
Unlike traditional vaccines that prevent infectious diseases, this treatment is highly personalized.
Scientists analyze the genetic code of a patient's specific tumor to create a custom vaccine.
While this treatment is still in the experimental stages, the results represent a historic milestone in oncology.
